J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -stud
$Johnson & Johnson(JNJ.US$ $SINOPHARM(01099.HK$ COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna(MRNA.US$ , $ASTRAZENECA PLC(AZNCF.US$ and $Pfizer(PFE.US$ and partner $BioNTech(BNTX.US$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline(GSK.US$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
MaxSureWin : cool
Evelynne :
Hummphry : i say, I say it ain't..yep I say it ain't looking good for $Pfizer (PFE.US)$ $Johnson & Johnson (JNJ.US)$ a lot of questionable information presented over the past several days.
YC Xiao : Sinopharm may be less effective but it's a conventional/traditional vaccine just like flu vaccine. It's not mrna. One is apple and the other is orange.